Dátum ex-dividendy spoločnosti Neovacs S.A
Aká je hodnota metriky Dátum ex-dividendy spoločnosti Neovacs S.A?
Hodnota metriky Dátum ex-dividendy spoločnosti Neovacs S.A. je N/A
Aká je definícia metriky Dátum ex-dividendy?
Dátum ex-dividendy (Ex-dividend date) je dátum, ktorý určuje či budú dividendy vyplatené predávajúcemu alebo kupujúcemu. Vyplatené dividendy za akcie kúpené po ex-dividend dátumom patria novému majiteľovi.
The ex-dividend date or reinvestment date is an investment term involving the timing of payment of dividends on stocks of corporations, income trusts, and other financial holdings. If a sale is before this date, the dividend belongs to the new owner; if on or after the date, the seller is entitled to the dividend. If a stock is purchased on its ex-dividend date or after, the buyer will not receive the next dividend payment. Instead, the seller gets the dividend. If a stock is purchased before the ex-dividend date, the buyer gets the dividend.
Čomu sa venuje spoločnosť Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.